Last reviewed · How we verify
MASCT-I
At a glance
| Generic name | MASCT-I |
|---|---|
| Also known as | Multiple Target Antigen Stimulating Cell Therapy |
| Sponsor | HRYZ Biotech Co. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma (PHASE2)
- A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors (PHASE1)
- MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma (EARLY_PHASE1)
- MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy. (PHASE1)
- A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor (PHASE1)
- Neo-MASCT Immunotherapy for Advanced NSCLC. (PHASE1, PHASE2)
- Study of Apatinib and MASCT in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- MASCT-I Treatment for Advanced Solid Tumor (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MASCT-I CI brief — competitive landscape report
- MASCT-I updates RSS · CI watch RSS
- HRYZ Biotech Co. portfolio CI